An evaluation of the role and treatment of elevated male hormones in autism spectrum disorders

• Autorzy: Geier D.A. , Kern J. K. , King P. G. , Sykes L. K. , Geier M. R.
• Języki publikacji: EN

Abstrakty

EN

Autism, Asperger's syndrome (AS), and pervasive developmental disorder - not otherwise specified (PDD-NOS) compose the overall diagnostic category of autism spectrum disorder (ASD). Subjects diagnosed with an ASD have a male:female ratio of 4:1, and among subjects diagnosed with AS the male:female ratio is as high as 9:1. The purpose of this study was to examine evidence of the association between hyperandrogenism and autistic traits (ATs) among subjects diagnosed with an ASD, and to evaluate the effectiveness of anti-androgen therapy as a means to help treat ATs in subjects diagnosed with an ASD. Evidence of hyperandrogenism in subjects diagnosed with an ASD is supported by multiple studies in the areas of psychological framework, brain pathology, tissue culture, and pre- and postnatal androgen levels. Data from subjects diagnosed with other conditions associated with elevated androgens reveals many of these individuals have ATs. Finally, in a placebo-controlled trial of testosterone administration to neurotypical subjects, testosterone was found to increase ATs. In addition, a controlled trial of human transsexuals revealed a significant increase in ATs in female-to-male transsexuals and a decrease in ATs in male-to-female transsexuals. Data from multiple animals and human clinical trials suggest that anti- androgen medications have the ability to significantly reduce ATs in patients diagnosed with an ASD. In light of the robust association between hyperandrogenism and ASD, it is recommended subjects diagnosed with an ASD should undergo routine screening for elevated androgens, and appropriate treatment should be initiated for those with elevated androgens.

• Wydawca: -
• Czasopismo: Acta Neurobiologiae Experimentalis
• Rocznik: 2012
• Tom: 72
• Numer: 1
• Opis fizyczny: p.1-17,ref.

Twórcy

autor

Geier D.A.

• The Institute of Chronic Illnesses, Inc., Silver Spring, MD, USA

autor

Kern J. K.

• The Institute of Chronic Illnesses, Inc., Silver Spring, MD, USA

autor

King P. G.

• CoMeD, Inc., Silver Spring, MD, USA

autor

Sykes L. K.

• CoMeD, Inc., Silver Spring, MD, USA

autor

Geier M. R.

• ASD Centers, LLC, Silver Spring, MD, USA

Bibliografia

• American Psychiatric Association (2000) Diagnostic criteria for autistic disorder. In Diagnostic and statistical manual of mental disorders, Fourth edition—text revision (DSMIV-TR). American Psychiatric Association, Washington, DC, pp. 75. Auyeung B, Baron-Cohen S, Chapman E, Knickmeyer RC, Taylor K, Hackett G (2006) Foetal testosterone and the child systemizing quotient. Eur J Endocrinol 155 :S123- S130.
• Auyeung B, Baron-Cohen S, Ashwin E, Knickmeyer R, Taylor K, Hackett G (2009) Fetal testosterone and autistic traits. Br J Psychol 100: 1-22.
• Auyeung B, Taylor K, Hackett G, Baron-Cohen S (2010) Foetal testosterone and autistic traits in 18 to 24-month- old children. Mol Autism 1: 11.
• Baron-Cohen S (2002) The extreme male brain theory of autism. Trends Cogn Sci 6: 248-254.
• Benson RC (1993) Total androgen blockade: the United States experience. Eur Urol 24 (Suppl 2): 72-76.
• Berenbaum SA, Resnick SM (1997) Early androgen effects on aggression in children and adults with congenital adre¬nal hyperplasia. Psychoneuroendocrinology 22: 505¬515.
• Bertelloni S, Mul D (2008) Treatment of central precocious puberty by GnRH analogs: long-term outcome in men. Asian J Androl 10: 525-534.
• Bryan KJ, Mudd JC, Richardson SL, Chang J, Lee HG, Zhu X, Smith MA, Casadesus G (2010) Down-regulation of serum gonadotropins is as effective as estrogen replace¬ment at improving menopause-associated cognitive defi¬cits. J Neurchem 112: 870-881.
• Caparros-Lefebvre D, Dewailly D (2005) Preliminary pilot study of cyproterone acetate for the treatment of aggres¬sive behavior associated with severe dementia. Rev Neurol (Pars) 161: 1071-1078.
• Carel JC, Eugster EA, Rogol A, Ghizzoni L, Palmert MR, ESPE-LWPES GnRH Analogs Consensus Conference Group (2009) Consensus statement on the use of gonado- tropin-releasing hormone analogs in children. Pediatrics 123: e752-e62.
• Chapman E, Baron-Cohen S, Auyeung B, Knickmeyer R, Taylor K, Hackett G (2006) Fetal testosterone and empa¬thy: evidence from the empathy quotient (EQ) and the 'Reading the mind in the eyes' test. Soc Neurosci 1: 135-148.
• Cohen-Bendahan CC, van de Beek C, Berenbaum SA (2005) Prenatal sex hormone effects on child and adult sex-typed behavior: methods and findings. Neurosci Biobehav Rev 29: 353-384.
• Collaer ML, Hines M (1995) Human behavioral sex differ¬ences: a role for gonadal hormones during early develop¬ment? Psychol Bull 118: 55-107.
• de Bruin EI, Veheij F, Wiegman T, Ferdinand RF (2006) Differences in finger length ratio between males with autism, pervasive developmental disorder-not otherwise specified, ADHD, and anxiety disorders. Dev Med Child Neurol 48: 962-965.
• Dorn LD, Hitt SF, Rotenstein D (1999) Biopsychological and cognitive differences in children with premature vs on-time adrenarche. Arch Pediatr Adolesc Med 153: 137-146.
• Eaton GG, Worlein JM, Kelley ST, Vijayaraghavan S, Hess DL, Axthelm MK, Bethea, CL (1999) Self-injurious behavior is decreased by cyproterone acetate in adult male rhesus (Macaca mulatta). Horm Behav 35: 195¬203.
• Eriksson T (2007) Anti-androgenic treatment of obsessive- compulsive disorder: an open-label clinical trial of the long-acting gonadotropin-releasing hormone analogue triporelin. Int Clin Psychopharmacol 22: 57-61.
• Finegan JA, Bartleman B, Wong PY (1989) A window for the study of prenatal sex hormone influences on postnatal development. J Genet Psychol 150: 101-112.
• Fombonne E (2005) The changing epidemiology of autism. J Appl Res Intellect Disabil 18: 281-294.
• Gaikward U, Parle M, Jumar A, Gaikwad D (2010) Effect of ritanserin and leuprolide alone and combined on marble-burying behavior of mice. Acta Pol Pharm 67: 523-527.
• Geier MR, Geier DA (2005) The potential importance of steroids in the treatment of autistic spectrum disorders and other disorders involving mercury toxicity. Med Hypotheses 64: 946-954.
• Geier DA, Geier MR (2006a) A clinical and laboratory evaluation of methionine cycle-transsulfuration and androgen pathway markers in children with autistic disor¬ders. Horm Res 66: 182-188.
• Geier DA, Geier MR (2006b) A clinical trial of combined anti-androgen and anti-heavy metal therapy in autistic disorders. Neuro Endocrinol Lett 27: 833-838.
• Geier DA, Geier MR (2007) A prospective assessment of androgen levels in patients with autistic spectrum disor¬ders: biochemical underpinnings and suggested therapies. Neuro Endocrinol Lett 28: 565-573.
• Geier DA, Geier MR (2008) Autism spectrum disorder-asso¬ciated biomarkers for case evaluation and management by clinical geneticists. Expert Rev Mol Diagn 8: 671¬674.
• Geier DA, Kern JK, Geier MR (2010) The biological basis of autism spectrum disorders: understanding causation and treatment by clinical geneticists. Acta Neurobiol Exp (Wars) 70: 209-226.
• Giedd JN, Snell JW, Lange N, Rajapakse JC, Casey BJ, Kozuch PL, Vaituzis AC, Vauss YC, Hamburger SD, Kaysen D, Rapoport JL (1996) Quantitative magnetic resonance imaging of human brain development: ages 4-18. Cereb Cortex 6: 551-560.
• Harden AY, Minshew NJ, Mallikaijuhn M, Keshavan MS (2001) Brain volume in autism. J Child Neurol 16: 421¬424.
• Hazlett HC, Poe M, Gerig G, Smith RG, Provenzale J, Ross A, Gilmore J, Piven J (2005) Magnetic resonance imaging and head circumference study of brain size in autism: birth through age 2 years. Arch Gen Psychiatry 62: 1366-1376.
• Higano CS (2003) Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology 61: 32-38.
• Hines M, Fane BA, Pasterski VL, Matthews GA, Conway GS, Brook C (2003) Spatial ability following prenatal androgen abnormality: targeting and mental rotations performance in individuals with congential adrenal hyper¬plasia. Psychoneuroendocrinology 28: 1010-1026.
• Hu VW, Nguyen A, Kim KS, Steinberg ME, Sarachana T, Scully MA, Soldin SJ, Luu T, Lee NH (2009) Gene expression profiling of lymphoblasts from autistic and nonaffected sib pairs: altered pathways in neuronal devel¬opment and steroid biosynthesis. PLoS One 4: e5775.
• Huertas D, Lopez-Ibor Alino JJ, Molina JD, Chamorro L, Balanza J, Jimenez MP, Hornillos M (2007) Antiaggressive effect of cyproterone versus haloperidol in Alzheimer's disease: a randomized double-blind pilot study. J Clin Psychiatry 68: 439-444.
• Jones RM, Wheelwright S, Farrell K, Martin E, Green R, Di Ceglie D, Baron-Cohen S (2012) Brief report: femaleto¬male transsexual people and autistic traits. J Autism Dev Disord 42: 301-306
• Judd HL, Robinson JD, Young PE, Jones OW (1976) Amniotic fluid testosterone levels in midpregnancy. Obstet Gynecol 48: 690-692.
• Kintzel PE, Chase SL, Schultz LM, O'Rourke TJ (2008) Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer. Pharmacotherapy 28: 1511-1522.
• Knickmeyer R, Baron-Cohen S, Raggatt P, Taylor K (2005) Foetal testosterone, social relationships, and restricted interests in children. J Child Psychol Psychiatry 46: 198-210.
• Knickmeyer R, Baron-Cohen S, Fane BA, Wheelwright S, Mathews GA, Conway GS, Brook CG, Hines M (2006) Androgens and autistic traits: a study of individuals with congenital adrenal hyperplasia. Horm Behav 50: 148¬153.
• Krajmer P, Spajdel M, Kubranska A, Ostatnikova D (2011) 2D:4D finger ratio in Slovak autism spectrum population. Bratisl Lek Listy 112: 377-379.
• Laron Z, Kauli R (2000) Experience with cyproterone ace¬tate in the treatment of precocious puberty. J Pediatr Endocrinol Metab 13 (Suppl 1): 805-810.
• Loosen PT, Purdon SE, Pavlou, SN (1994) Effects on behav¬ior of modulation of gonadal function in men with gonadotropin-releasing hormone antagonists. Am J Psychiatry 151: 271-273.
• Lutchmaya S, Baron Cohen S, Raggatt P (2002a) Foetal testosterone and eye contact in 12 month old infants. Infant Behav Dev 25: 327-335.
• Lutchmaya S, Baron-Cohen S, Raggatt P (2002b) Foetal testosterone and vocabulary size in 18- and 24-months- old infants. Infant Behav Dev 24: 418-424.
• Lutchmaya S, Baron-Cohen S, Raggatt P, Knickmeyer R, Manning JT (2004) 2nd to 4th digit ratios, fetal testosterone and estradiol. Early Hum Dev 77: 23-28.
• MacLeod TL, Eisen A, Sussman GL (1987) Anaphylactic reaction to synthetic luteinizing hormone-releasing hor¬mone. Fertil Steril 48: 500-502.
• Majewska MD, Hill M, Urbanowicz E, Rok-Bojko P, Namyslowska I, Mierzejewski P (2010) Different levels of salivary steroids in autistic and health children. Eur. Neuropsychopharmacol 20(Suppl 3): S615-S616.
• Majiakou MA, Manousaki D, Papadaki M, Hadjidakis D, Levidous G, Vakaki M, Papaefstathiou A, Lalioti N, Kanaka-Gantenbein C, Piaditis G, Chrousos GP, Dacou- Voutetakis C (2010) The efficacy and safety of gonadotropin-releasing hormone analog treatment in childhood and adolescence: a single center, long-term follow-up study. J Clin Endocrinol Metab 95: 109-117.
• Malas MA, Dogan S, Evcil EH, Desdicioglu K (2006) Fetal development of the hand, digits and digit ratio (2D:4D). Early Hum Dev 82: 469-475.
• Malone RP, Waheed A (2009) The role of antipsychotics in the management of behavioral symptoms in children and adolescents with autism. Drugs 69: 535-548.
• Manning JT, Scutt D, Wilson J, Lewis-Jones DI (1998) The ratio of 2nd to 4th digit length: a predictor of sperum num¬bers and concentrations of testosterone, luteinizing hor¬mone and oestrogen. Hum Reprod 13: 3000-3004.
• Manning JT, Baron-Cohen S, Wheelwright S, Sanders G (2001) The 2nd to 4th digit ratio and autism. Dev Med Child Neurol 43: 160-164.
• Milne E, White S, Campbell R, Swettenham J, Hansen P, Ramus F (2006) Motion and form coherence detection in autistic spectrum disorder: relationship to motor control and 2:4 digit ratio. J Autism Dev Disord 36: 225-237.
• Neely EK, Lee PA, Bloch CA, Larsen L, Yang D, Mattia- Goldberg C, Chwalisz K (2010) Leuprolide acetate 1-month depot for central precocious puberty: hormonal suppression and recovery. Int J Pediatr Endocrinol 2010: 398639.
• New MI (1998) Diagnosis and management of congenital adrenal hyperplasia. Annu Rev Med 49: 311-328.
• Noipayak P (2009) The ratio of 2nd and 4th digit length in autistic children. J Med Assoc Thai 92: 1040-1045.
• Partsch CJ, Sippell WG (2002) Treatment of central preco¬cious puberty. Best Pract Res Clin Endocrinol Metab 16: 165-189.
• Reismann P, Liko I, Igaz P, Patocs A, Racz K (2009) Pharmacological options for treatment of hyperandrogenic disorders. Mini Rev Med Chem 9: 1113-1126.
• Ruta L, Ingudomnukul E, Taylor K, Chakrabati B, Baron¬Cohen S (2011) Increased serum androstenedione in adults with autism spectrum conditions. Psychoneuroendocrinology 36: 1154-1163.
• Rutter M, Caspi A, Moffitt TE (2003) Using sex differences in psychopathology to study causal mechanisms: unifying issues and research strategies. J Child Psychol Psychiatry 44: 1092-1115.
• Sarachana T, Xu M, Wu RC, Hu VW (2011) Sex hormones in autism: androgens and estrogens differentially and reciprocally regulate RORA, a novel candidate gene for autism. PLoS One 6: e17116.
• Schindler AE (1982) Hormones in human amniotic fluid. Monogr Endocrinol 21: 1-158.
• Schwarz E, Guest PC, Rahmoune H, Wang L, Levin Y, Ingodomnukul E, Ruta L, Kent L, Spain M, Baron-Cohen S, Bahn S (2011) Sex-specific serum biomarker patterns in adults with Asperger's syndrome. Mol Psychiatry 16: 1213-1220.
• Scott FJ, Baron-Cohen S, Bolton P, Brayne C (2002) Brief report: prevalence of autism spectrum conditions in chil¬dren aged 5-11 years in Cambridgeshire, UK. Autism 6: 231-237.
• Smith LL, Hines M (2000) Language lateralization and handedness in women prenatally exposed to diethylstilbestrol (DES). Psychoneuroendocrinology 25: 497¬512.
• Takagishi H, Takahashi T, Yamagishi T, Shinada M, Inukai K, Tanida S, Mifune N, Horita Y, Hashimoto H, Yang Y, Kameda T (2010) Salivary testosterone levels and autism spectrum quotient in adults. Neuro Endocrinol Lett 31: 837-841.
• Tanaka T, Niimi H, Matsuo N, Fujieda K, Tachibana K, Ohyama K, Satoh M, Kugu K (2005) Results of long- term follow-up after treatment of central precocious puberty with leuprorelin acetate: evaluation of effective¬ness of treatment and recovery of gonadal function. The TAP144-SP Japanese Study Group on Central Precocious Puberty. J Clin Endocrinol Metab 90: 1371-1376.
• Tordjman S, Ferrari P, Sulmont V, Dume M, Roubertoux P (1997) Androgenic activity in autism. Am J Psychiatry 154: 1626-1627.
• Torri V, Floriani I (2005) Cyproterone acetate in the therapy of prostate carcinoma. Arch Ital Urol Androl 77: 157-163.
• Uday G, Pravinkumar B, Manish W, Sudhir U (2007) LHRH antagonist attenuates the effect of fluoxetine on marble- burying behavior in mice. Eur J Pharmacol 563: 155-159.
• Umathe S, Bhutada P, Dixit P, Shende V (2008a) Increased marble-burying behavior in ethanol-withdrawal state: modulation by gonadotropin-releasing hormone agonist. Eur J Pharmacol 587: 175-180.
• Umathe SN, Bhutada PS, Dixit PV, Jain NS (2008b) Leuprolide: a luteinizing hormone releasing agonist attenuated ethanol withdrawal syndrome and ethanol-in- duced locomotor sensitization in mice. Neuropeptides 42: 345-353.
• Umathe SN, Bhutada PS, Jain NS, Dixit PV, Wanjari MM (2008c) Effects of central administration of gonadotropin-releasing hormone agonists and antagonist on elevat¬ed plus-maze and social interaction behavior in rats. Behav Pharmacol 19: 308-316.
• Umathe SN, Bhutada PS, Jain NS, Shukla NR, Mundhaha YR, Dixit PV (2008d) Gonadotropin-releasing hormone agonist blocks anxiogenic-like and depressant-like effect ofcorticotrophin-releasing hormone in mice. Neuropeptides 42: 399-410.
• Umathe SN, Wanjari MM, Manna SS, Jain NS (2009) A pos¬sible participation of gonadotropin-releasing hormone in the neuroleptic and cataleptic effect of haloperidol. Neuropeptides 43: 251-257.
• van der Sluis IM, Boot AM, Krenning EP, Drop SL, de Muinck Keizer-Schrama SM (2002) Longitudinal follow- up of bone density and body composition in children with precocious or early puberty before, during and after ces¬sation of GnRH agonist therapy. J Clin Endocrinol Metab 87: 506-512.
• van Honk J, Schutter DJ, Bos PA, Kruijt AW, Lentjes EG, Baron-Cohen S (2011) Testosterone administration impairs cognitive empathy in women depending on sec¬ond-to-fourth digit ratio. Proc Natl Acad Sci U S A 108: 3448-3452.
• Wojniusz S, Vogele C, Ropstad E, Evans N, Robinson J, Sutterlin S, Erhard HW, Solbakk AK, Endestad T, Olberg DE, Haraldsen IR (2011) Prepubertal gonadotropin-re- leasing hormone analog leads to exaggerated behavioral and emotional sex differences in sheep. Horm Behav 59: 22-27.

Uwagi

Rekord w opracowaniu